Literature DB >> 18728359

Long-term prognosis of steroid-dependent sensorineural hearing loss.

Jin Kanzaki1, Sho Kanzaki, Kaoru Ogawa.   

Abstract

We report on the long-term follow-up of 15 patients with steroid-dependent sensorineural hearing loss (SDSNHL), which was steroid dose dependent. We classified the patients into 2 groups: group A consisted of 6 patients with systemic SDSNHL, and group B consisted of 9 patients with inner-ear-specific SDSNHL without systemic disease. Group B patients were further classified as patients with slowly or rapidly progressive hearing loss. The yearly rate of hearing deterioration was greater in group B than in group A. Thus, the long-term hearing prognosis of patients in group B was worse than those in group A. Although SDSNHL may have immune-related origins, we hypothesize that hearing deterioration may be caused by proinflammatory cytokines because many of our cases exhibited abnormal immunological laboratory values and because many of these cases responded favorably to steroid treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18728359     DOI: 10.1159/000151587

Source DB:  PubMed          Journal:  Audiol Neurootol        ISSN: 1420-3030            Impact factor:   1.854


  4 in total

1.  Vascular Pathophysiology in Hearing Disorders.

Authors:  Dennis R Trune; Anh Nguyen-Huynh
Journal:  Semin Hear       Date:  2012-08

Review 2.  Ion homeostasis in the ear: mechanisms, maladies, and management.

Authors:  Dennis R Trune
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2010-10       Impact factor: 2.064

Review 3.  Corticosteroid therapy for hearing and balance disorders.

Authors:  Dennis R Trune; Barbara Canlon
Journal:  Anat Rec (Hoboken)       Date:  2012-10-08       Impact factor: 2.064

4.  Familial HLA-B*52 Vasculitis: Maternal, Atypical Cogan's Syndrome with Takayasu Arteritis-mimicking Aortitis and Filial Takayasu Arteritis.

Authors:  Satoshi Morinaka; Yohei Takano; Hiroto Tsuboi; Daisuke Goto; Takayuki Sumida
Journal:  Intern Med       Date:  2020-04-23       Impact factor: 1.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.